28 Jan 2020
-
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved
505(b)(2) product in the cardiovascular space. US rights only. Asset
has significant intellectual property rights. This p... View Release
6 Aug 2018
-
Opportunity to Acquire over 160 ANDA's
Commercial Healthcare Partners announces an opportunity to
acquire over 160 ANDAs from a single source.
Interested bidders can
acquire one or more of these assets.
Therapeutic... View Release
16 Jun 2017
-
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of Head and Neck Cancer
PNP Therapeutics:
BIRMINGHAM, Ala. - PNP Therapeutics Inc.
announced today the Food and Drug Administration has granted orphan drug status
to Gedeptin, the Company's lead product cand... View Release
11 May 2017
-
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.
"CHP client signs an agreement to commercialize its
505(b)(2) asset for the treatment of glaucoma.
The product is currently undergoing FDA review."
5 Jul 2016
-
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance
of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP)
associated with resistance to immune tolerance. This... View Release
13 Jan 2016
-
CHP attended the Biotech Showcase partnering meeting
Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco. More than 30 meetings were held with... View Release
25 Oct 2015
-
CHP collaboration with Finston Consulting
Commercial Healthcare Partners is pleased to announce a collaboration with Finston Consulting based in Washington, D.C. Finston Consulting will provide data room collection and management ser... View Release
27 Mar 2015
-
SynAllergy seeks sales representatives and contract sales organizations
SynAllergy seeks sales representatives and contract sales organizations to call on primary care physicians, pediatricians and other healthcare providers. Representatives receive a subst... View Release
6 Nov 2014
-
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
WIXOM, Mich., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD)... View Release
12 Aug 2014
-
Diabetic Retinopathy/Diabetic Macular Edema Compound
Established company with strong IP rights to early stage compound for the treatment of Diabetic Retinopathy/Diabetic Macular Edema wishes to discuss divestiture. Compound is supported by limi... View Release
11 Apr 2013
-
Rockwell Medical - SFP
What's happening NOW! Rockwell Medical Soluble
Ferric Pyrophosphate (SFP) Phase
III asset available from Rockwell Medicaland
24 Apr 2012
-
Novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease
Commercial Healthcare Partners is pleased to announce the availability of a novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease. This product is by product of nicot... View Release
4 Dec 2011
-
Head Lice Product available for in-licensing ex U.S.
Client company has product available for licensing in multiple countries outside the U.S. Product is not an insecticide and is available in the U.S. through a distribution partner that is wel... View Release
18 Apr 2011
-
Smoking Cessation
Company holds intellectual property rights to a unique combination of currently marketed products for smoking cessation. Company is interested in a partner to assist in further development an... View Release
15 Apr 2011
-
Locking Solution
A Unique locking solution being offered as an alternative to heparin. This technology is in the early stages of development. For more information, contact Commercial Healthcare Partners.
5 Mar 2011
-
Dry Eye Syndrome
Compound with unique transdermal delivery in Phase I development for the treatment of Dry Eye Syndrome. Company seeks development or licensing opportunity. Data presented to the America... View Release
2 Mar 2011
-
Product in Phase IIB
Compound available for licensing and/or development partnership. This product has been designated an orphan drug by the FDA for the treatment of Scleroderma. Additional patent is pendin... View Release
|
|
|
|
|
